LPA and coronary artery disorder: The advent of novel lipid-modifying agents beyond LDL-C-lowering for prevention of CHD has prompted interest in Lp(a) and other apolipoprotein assays to facilitate targeted treatment for residual lipid-related risk in patients at high risk of CHD.17,36,37 Pelacarsen (Ionis Pharmaceuticals) is an antisense oligonucleotide designed to reduce Lp(a).